Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ID/g (ADMET) | = 0.13 % | Biodistribution of the compound after 6 hours of postinjection in brain | ChEMBL. | 10893312 |
ID/g (ADMET) | = 0.26 % | Biodistribution of the compound after 6 hours of postinjection in muscle | ChEMBL. | 10893312 |
ID/g (ADMET) | = 0.32 % | Biodistribution of the compound after 1 hour of postinjection in brain | ChEMBL. | 10893312 |
ID/g (ADMET) | = 0.57 % | Biodistribution of the compound after 1 hour of postinjection in muscle | ChEMBL. | 10893312 |
ID/g (ADMET) | = 0.86 % | Biodistribution of the compound after 6 hours of postinjection in heart | ChEMBL. | 10893312 |
ID/g (ADMET) | = 1.3 % | Biodistribution of the compound after 6 hours of postinjection in blood | ChEMBL. | 10893312 |
ID/g (ADMET) | = 1.39 % | Biodistribution of the compound after 6 hours of postinjection in melanoma | ChEMBL. | 10893312 |
ID/g (ADMET) | = 1.44 % | Biodistribution of the compound after 6 hours of postinjection in spleen | ChEMBL. | 10893312 |
ID/g (ADMET) | = 2.09 % | Biodistribution of the compound after 1 hour of postinjection in heart | ChEMBL. | 10893312 |
ID/g (ADMET) | = 2.88 % | Biodistribution of the compound after 1 hour of postinjection in melanoma | ChEMBL. | 10893312 |
ID/g (ADMET) | = 3.28 % | Biodistribution of the compound after 1 hour of postinjection in blood | ChEMBL. | 10893312 |
ID/g (ADMET) | = 5.5 % | Biodistribution of the compound after 6 hours of postinjection in lungs | ChEMBL. | 10893312 |
ID/g (ADMET) | = 6.04 % | Biodistribution of the compound after 1 hour of postinjection in spleen | ChEMBL. | 10893312 |
ID/g (ADMET) | = 7.23 % | Biodistribution of the compound after 6 hours of postinjection in liver | ChEMBL. | 10893312 |
ID/g (ADMET) | = 12.9 % | Biodistribution of the compound after 6 hours of postinjection in kidney | ChEMBL. | 10893312 |
ID/g (ADMET) | = 13.2 % | Biodistribution of the compound after 1 hour of postinjection in lungs | ChEMBL. | 10893312 |
ID/g (ADMET) | = 16.6 % | Biodistribution of the compound after 1 hour of postinjection in liver | ChEMBL. | 10893312 |
ID/g (ADMET) | = 24 % | Biodistribution of the compound after 1 hour of postinjection in kidney | ChEMBL. | 10893312 |
logD (ADMET) | = 0.95 pH7.4 | Partition coefficient (logD7.4) | ChEMBL. | 10893312 |
logP (ADMET) | = 3.6 | Partition coefficient of the unprotonated free amine (logP) | ChEMBL. | 10893312 |
pKa | = 9.6 | aqueous ionization constant (pKa) determined by HPLC methods | ChEMBL. | 10893312 |
Ratio (ADMET) | < 1 | Biodistribution of the compound after 1 hour of postinjection in melanoma/blood | ChEMBL. | 10893312 |
Ratio (ADMET) | < 1 | Biodistribution of the compound after 1 hour of postinjection in melanoma/spleen | ChEMBL. | 10893312 |
Ratio (ADMET) | < 1 | Biodistribution of the compound after 6 hours of postinjection in melanoma/spleen | ChEMBL. | 10893312 |
Ratio (ADMET) | < 1 | Biodistribution of the compound after 1 hour of postinjection in melanoma/lungs | ChEMBL. | 10893312 |
Ratio (ADMET) | < 1 | Biodistribution of the compound after 6 hours of postinjection in melanoma/lungs | ChEMBL. | 10893312 |
Ratio (ADMET) | < 1 | Biodistribution of the compound after 1 hour of postinjection in melanoma/liver | ChEMBL. | 10893312 |
Ratio (ADMET) | < 1 | Biodistribution of the compound after 6 hours of postinjection in melanoma/liver | ChEMBL. | 10893312 |
Ratio (ADMET) | = 1.1 | Biodistribution of the compound after 6 hours of postinjection in melanoma/blood | ChEMBL. | 10893312 |
tR (binding) | = 8.9 min | RP-HPLC comparison of Rhenium complexes with analogous '3+1' mixed-ligand | ChEMBL. | 10893312 |
tR (binding) | = 10 min | RP-HPLC comparison of Tecnetium-99 complexes with analogous '3+1' mixed-ligand | ChEMBL. | 10893312 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.